This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survi

Summit partner Akeso reports 30.8-month median OS for ivonescimab vs 22.6 for pembrolizumab in lung

Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Impr

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and

Stocks rallied and Treasury yields retreated from three-year highs after Fed Governor Waller signale

Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake

Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive ov

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab

Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. E

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive to

Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-f

Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings

Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to M

First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Be